Critères d’évaluation

Critères d’évaluation1,2

Mesuré par l’analyse Abbott RealTime VIH-1.
DOR/3TC/TDF : doravirine (100 mg) / lamivudine (300 mg) / fumarate de ténofovir disoproxil (300 mg). IP = inhibiteur de protéase; ARN = acide ribonucléique; FDA = Food and Drug Administration.

Bibliographie:

  1. Johnson M, Kumar P, Molina JM, et al. Switching to Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate
    (DOR/3TC/TDF) Maintains HIV-1 Virologic Suppression Through 48 Weeks: Results of the DRIVE-SHIFT Trial. J Acquir Immune Defic Syndr. 2019;81(4):463-472.
  2. Supplement to: Johnson M, Kumar P, Molina JM, et al. Switching to Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (DOR/3TC/TDF) Maintains HIV-1 Virologic Suppression Through 48 Weeks: Results of the DRIVE-SHIFT Trial. J Acquir Immune Defic Syndr. 2019;81(4):463-472.

DZ-DOR-00009. Date d’expiration: 1-10-2026